Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Pregabalin
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
AG-Pregabalin · DIN 02480727 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Pregabalin · DIN 02480727
Manufacturer: Angita Pharma Inc.; listing date 2020-11-30
Health Canada: Marketed since 2018-09-28 · brand AG-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Angita pharma inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAG-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02480727)
Source record
DIN 02480727: AG-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id ANG
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02480727
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97125
Interchangeable products
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02480727
Shortage record checked October 6, 2026
Ach-Pregabalin · DIN 02449838 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Pregabalin · DIN 02449838
Manufacturer: Accord Healthcare Inc.; listing date 2021-08-31
Health Canada: Marketed since 2021-05-27 · brand ACH-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAch-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02449838)
Source record
DIN 02449838: Ach-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id ACH
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02449838
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93569
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended November 2, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02449838
Shortage record checked October 6, 2026
Auro-Pregabalin · DIN 02433869 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Pregabalin · DIN 02433869
Manufacturer: Auro Pharma Inc.; listing date 2015-05-28
Health Canada: Marketed since 2015-03-02 · brand AURO-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02433869)
Source record
DIN 02433869: Auro-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id AUR
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02433869
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91825
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended January 6, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02433869
Shortage record checked October 6, 2026
Bio-Pregabalin · DIN 02541122 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Bio-Pregabalin · DIN 02541122
Manufacturer: Biomed Pharma; listing date 2026-07-31
Health Canada: Marketed since 2024-02-29 · brand BIO-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Biomed pharma · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordBio-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02541122)
Source record
DIN 02541122: Bio-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id BMP
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02541122
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102979
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02541122
Shortage record checked October 6, 2026
Jamp-Pregabalin · DIN 02435977 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Pregabalin · DIN 02435977
Manufacturer: Jamp Pharma Corporation; listing date 2016-01-28
Health Canada: Marketed since 2019-10-01 · brand JAMP-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02435977)
Source record
DIN 02435977: Jamp-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id JPC
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02435977
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92031
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02435977
Shortage record checked October 6, 2026
Lyrica · DIN 02268418 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Savings card: RxHelp ONE lists Lyrica (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Lyrica · DIN 02268418
Manufacturer: Upjohn Canada ULC; listing date 2013-04-30
Health Canada: Marketed since 2023-05-11 · brand LYRICA · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Bgp pharma ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02268418)
Source record
DIN 02268418: Lyrica
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id UJC
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $1.0222; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02268418
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75379
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended August 1, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02268418
Shortage record checked October 6, 2026
M-Pregabalin · DIN 02467291 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Pregabalin · DIN 02467291
Manufacturer: Mantra Pharma Inc.; listing date 2021-09-30
Health Canada: Marketed since 2023-10-06 · brand M-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordM-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02467291)
Source record
DIN 02467291: M-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id MAT
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02467291
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95568
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended January 14, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02467291
Shortage record checked October 6, 2026
Mar-Pregabalin · DIN 02417529 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Pregabalin · DIN 02417529
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-05-29
Health Canada: Marketed since 2022-04-28 · brand MAR-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMar-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02417529)
Source record
DIN 02417529: Mar-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id MAR
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02417529
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90207
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: active shortage (reported October 1, 2017, last updated July 5, 2018) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02417529
Shortage record checked October 6, 2026
Mint-Pregabalin · DIN 02423804 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Pregabalin · DIN 02423804
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-08-28
Health Canada: Marketed since 2014-06-12 · brand MINT-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02423804)
Source record
DIN 02423804: Mint-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id MIN
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02423804
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90851
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended February 2, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02423804
Shortage record checked October 6, 2026
NRA-Pregabalin · DIN 02479117 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Pregabalin · DIN 02479117
Manufacturer: Nora Pharma; listing date 2020-07-31
Health Canada: Marketed since 2018-10-22 · brand NRA-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02479117)
Source record
DIN 02479117: NRA-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id NRA
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02479117
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96708
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02479117
Shortage record checked October 6, 2026
Nat-Pregabalin · DIN 02494841 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Nat-Pregabalin · DIN 02494841
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-02-28
Health Canada: Marketed since 2020-05-07 · brand NAT-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Natco pharma (canada) inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNat-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02494841)
Source record
DIN 02494841: Nat-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id NAT
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02494841
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98482
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02494841
Shortage record checked October 6, 2026
PMS-Pregabalin · DIN 02359596 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Pregabalin · DIN 02359596
Manufacturer: Pharmascience Inc.; listing date 2013-04-30
Health Canada: Marketed since 2013-02-14 · brand PMS-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02359596)
Source record
DIN 02359596: PMS-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id PMS
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02359596
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84460
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended April 17, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02359596
Shortage record checked October 6, 2026
Pregabalin · DIN 02403692 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Pregabalin · DIN 02403692
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-07-31
Health Canada: Marketed since 2021-08-20 · brand PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02403692)
Source record
DIN 02403692: Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id SIV
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02403692
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88848
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: Reversed (report reversed by the reporter); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02403692
Shortage record checked October 6, 2026
Pregabalin · DIN 02405539 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Pregabalin · DIN 02405539
Manufacturer: Sanis Health Inc.; listing date 2016-05-31
Health Canada: Marketed since 2016-01-27 · brand PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02405539)
Source record
DIN 02405539: Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id SAI
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02405539
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89032
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended March 8, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02405539
Shortage record checked October 6, 2026
Ran-Pregabalin · DIN 02392801 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Pregabalin · DIN 02392801
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2013-04-30
Health Canada: Marketed since 2020-06-02 · brand TARO-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRan-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02392801)
Source record
DIN 02392801: Ran-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id RAN
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02392801
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87804
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: active shortage (reported February 11, 2026, estimated to end October 30, 2026, last updated September 14, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02392801
Shortage record checked October 6, 2026
Sandoz Pregabalin · DIN 02390817 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Pregabalin · DIN 02390817
Manufacturer: Sandoz Canada Inc.; listing date 2013-04-30
Health Canada: Marketed since 2013-02-15 · brand SANDOZ PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02390817)
Source record
DIN 02390817: Sandoz Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id SDZ
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02390817
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87621
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Teva-Pregabalin · DIN 02361159 · $0.1481
Shortage status: resolved shortage (ended March 20, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02390817
Shortage record checked October 6, 2026
Teva-Pregabalin · DIN 02361159 · 25 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Pregabalin · DIN 02361159
Manufacturer: Teva Canada Limited; listing date 2013-04-30
Health Canada: Marketed since 2013-03-06 · brand TEVA-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 25 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Pregabalin: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1481). What the ministry pays, not the patient.
Ministry pays: $0.1481 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02361159)
Source record
DIN 02361159: Teva-Pregabalin
Raw flags: sec3=Y
Item: 281200094; group id 442; item number 1103; lccId None; manufacturer id TEV
Source form: Cap; strength: 25mg
Recorded listing: General benefit
Source prices (unrounded): $0.1481; ministry $0.1481
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02361159
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84620
Interchangeable products
AG-Pregabalin · DIN 02480727 · $0.1481
Ach-Pregabalin · DIN 02449838 · $0.1481
Apo-Pregabalin · DIN 02394235 · $0.1481
Auro-Pregabalin · DIN 02433869 · $0.1481
Bio-Pregabalin · DIN 02541122 · $0.1481
Co Pregabalin · DIN 02402912 · $0.1481
Jamp-Pregabalin · DIN 02435977 · $0.1481
Lyrica · DIN 02268418 · $0.1481
M-Pregabalin · DIN 02467291 · $0.1481
Mar-Pregabalin · DIN 02417529 · $0.1481
Mint-Pregabalin · DIN 02423804 · $0.1481
NRA-Pregabalin · DIN 02479117 · $0.1481
Nat-Pregabalin · DIN 02494841 · $0.1481
PMS-Pregabalin · DIN 02359596 · $0.1481
Pregabalin · DIN 02403692 · $0.1481
Pregabalin · DIN 02405539 · $0.1481
Ran-Pregabalin · DIN 02392801 · $0.1481
Sandoz Pregabalin · DIN 02390817 · $0.1481
Shortage status: discontinued (March 23, 2022, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02361159
Shortage record checked October 6, 2026
AG-Pregabalin · DIN 02480735 · 50 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Pregabalin · DIN 02480735
Manufacturer: Angita Pharma Inc.; listing date 2020-11-30
Health Canada: Marketed since 2018-09-28 · brand AG-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Angita pharma inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAG-Pregabalin: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2324). What the ministry pays, not the patient.
Ministry pays: $0.2324 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02480735)
Source record
DIN 02480735: AG-Pregabalin
Raw flags: sec3=Y
Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id ANG
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.2324; ministry $0.2324
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02480735
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97126
Interchangeable products
Ach-Pregabalin · DIN 02449846 · $0.2324
Apo-Pregabalin · DIN 02394243 · $0.2324
Auro-Pregabalin · DIN 02433877 · $0.2324
Bio-Pregabalin · DIN 02541130 · $0.2324
Co Pregabalin · DIN 02402920 · $0.2324
Jamp-Pregabalin · DIN 02435985 · $0.2324
Lyrica · DIN 02268426 · $0.2324
M-Pregabalin · DIN 02467305 · $0.2324
Mar-Pregabalin · DIN 02417537 · $0.2324
Mint-Pregabalin · DIN 02423812 · $0.2324
NRA-Pregabalin · DIN 02479125 · $0.2324
Nat-Pregabalin · DIN 02494868 · $0.2324
PMS-Pregabalin · DIN 02359618 · $0.2324
Pregabalin · DIN 02403706 · $0.2324
Pregabalin · DIN 02405547 · $0.2324
Ran-Pregabalin · DIN 02392828 · $0.2324
Sandoz Pregabalin · DIN 02390825 · $0.2324
Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02480735
Shortage record checked October 6, 2026
Ach-Pregabalin · DIN 02449846 · 50 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ach-Pregabalin · DIN 02449846
Manufacturer: Accord Healthcare Inc.; listing date 2021-08-31
Health Canada: Marketed since 2021-05-27 · brand ACH-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAch-Pregabalin: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2324). What the ministry pays, not the patient.
Ministry pays: $0.2324 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02449846)
Source record
DIN 02449846: Ach-Pregabalin
Raw flags: sec3=Y
Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id ACH
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.2324; ministry $0.2324
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02449846
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93570
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324
Apo-Pregabalin · DIN 02394243 · $0.2324
Auro-Pregabalin · DIN 02433877 · $0.2324
Bio-Pregabalin · DIN 02541130 · $0.2324
Co Pregabalin · DIN 02402920 · $0.2324
Jamp-Pregabalin · DIN 02435985 · $0.2324
Lyrica · DIN 02268426 · $0.2324
M-Pregabalin · DIN 02467305 · $0.2324
Mar-Pregabalin · DIN 02417537 · $0.2324
Mint-Pregabalin · DIN 02423812 · $0.2324
NRA-Pregabalin · DIN 02479125 · $0.2324
Nat-Pregabalin · DIN 02494868 · $0.2324
PMS-Pregabalin · DIN 02359618 · $0.2324
Pregabalin · DIN 02403706 · $0.2324
Pregabalin · DIN 02405547 · $0.2324
Ran-Pregabalin · DIN 02392828 · $0.2324
Sandoz Pregabalin · DIN 02390825 · $0.2324
Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: resolved shortage (ended September 10, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02449846
Shortage record checked October 6, 2026
Apo-Pregabalin · DIN 02394243 · 50 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Pregabalin · DIN 02394243
Manufacturer: Apotex Inc.; listing date 2013-04-30
Health Canada: Marketed since 2026-08-14 · brand APO-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Pregabalin: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2324). What the ministry pays, not the patient.
Ministry pays: $0.2324 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02394243)
Source record
DIN 02394243: Apo-Pregabalin
Raw flags: sec3=Y
Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id APX
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.2324; ministry $0.2324
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02394243
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87940
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324
Ach-Pregabalin · DIN 02449846 · $0.2324
Auro-Pregabalin · DIN 02433877 · $0.2324
Bio-Pregabalin · DIN 02541130 · $0.2324
Co Pregabalin · DIN 02402920 · $0.2324
Jamp-Pregabalin · DIN 02435985 · $0.2324
Lyrica · DIN 02268426 · $0.2324
M-Pregabalin · DIN 02467305 · $0.2324
Mar-Pregabalin · DIN 02417537 · $0.2324
Mint-Pregabalin · DIN 02423812 · $0.2324
NRA-Pregabalin · DIN 02479125 · $0.2324
Nat-Pregabalin · DIN 02494868 · $0.2324
PMS-Pregabalin · DIN 02359618 · $0.2324
Pregabalin · DIN 02403706 · $0.2324
Pregabalin · DIN 02405547 · $0.2324
Ran-Pregabalin · DIN 02392828 · $0.2324
Sandoz Pregabalin · DIN 02390825 · $0.2324
Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: active shortage (reported November 12, 2024, last updated November 14, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02394243
Shortage record checked October 6, 2026
Auro-Pregabalin · DIN 02433877 · 50 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Pregabalin · DIN 02433877
Manufacturer: Auro Pharma Inc.; listing date 2015-05-28
Health Canada: Marketed since 2015-03-02 · brand AURO-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Pregabalin: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2324). What the ministry pays, not the patient.
Ministry pays: $0.2324 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02433877)
Source record
DIN 02433877: Auro-Pregabalin
Raw flags: sec3=Y
Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id AUR
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.2324; ministry $0.2324
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02433877
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91826
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324
Ach-Pregabalin · DIN 02449846 · $0.2324
Apo-Pregabalin · DIN 02394243 · $0.2324
Bio-Pregabalin · DIN 02541130 · $0.2324
Co Pregabalin · DIN 02402920 · $0.2324
Jamp-Pregabalin · DIN 02435985 · $0.2324
Lyrica · DIN 02268426 · $0.2324
M-Pregabalin · DIN 02467305 · $0.2324
Mar-Pregabalin · DIN 02417537 · $0.2324
Mint-Pregabalin · DIN 02423812 · $0.2324
NRA-Pregabalin · DIN 02479125 · $0.2324
Nat-Pregabalin · DIN 02494868 · $0.2324
PMS-Pregabalin · DIN 02359618 · $0.2324
Pregabalin · DIN 02403706 · $0.2324
Pregabalin · DIN 02405547 · $0.2324
Ran-Pregabalin · DIN 02392828 · $0.2324
Sandoz Pregabalin · DIN 02390825 · $0.2324
Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: resolved shortage (ended February 18, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02433877
Shortage record checked October 6, 2026
Bio-Pregabalin · DIN 02541130 · 50 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Bio-Pregabalin · DIN 02541130
Manufacturer: Biomed Pharma; listing date 2026-07-31
Health Canada: Marketed since 2024-03-11 · brand BIO-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Biomed pharma · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordBio-Pregabalin: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2324). What the ministry pays, not the patient.
Ministry pays: $0.2324 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02541130)
Source record
DIN 02541130: Bio-Pregabalin
Raw flags: sec3=Y
Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id BMP
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.2324; ministry $0.2324
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02541130
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102980
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324
Ach-Pregabalin · DIN 02449846 · $0.2324
Apo-Pregabalin · DIN 02394243 · $0.2324
Auro-Pregabalin · DIN 02433877 · $0.2324
Co Pregabalin · DIN 02402920 · $0.2324
Jamp-Pregabalin · DIN 02435985 · $0.2324
Lyrica · DIN 02268426 · $0.2324
M-Pregabalin · DIN 02467305 · $0.2324
Mar-Pregabalin · DIN 02417537 · $0.2324
Mint-Pregabalin · DIN 02423812 · $0.2324
NRA-Pregabalin · DIN 02479125 · $0.2324
Nat-Pregabalin · DIN 02494868 · $0.2324
PMS-Pregabalin · DIN 02359618 · $0.2324
Pregabalin · DIN 02403706 · $0.2324
Pregabalin · DIN 02405547 · $0.2324
Ran-Pregabalin · DIN 02392828 · $0.2324
Sandoz Pregabalin · DIN 02390825 · $0.2324
Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02541130
Shortage record checked October 6, 2026
Jamp-Pregabalin · DIN 02435985 · 50 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Pregabalin · DIN 02435985
Manufacturer: Jamp Pharma Corporation; listing date 2016-01-28
Health Canada: Marketed since 2018-07-25 · brand JAMP-PREGABALIN · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Pregabalin: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2324). What the ministry pays, not the patient.
Ministry pays: $0.2324 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02435985)
Source record
DIN 02435985: Jamp-Pregabalin
Raw flags: sec3=Y
Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id JPC
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.2324; ministry $0.2324
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02435985
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92032
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324
Ach-Pregabalin · DIN 02449846 · $0.2324
Apo-Pregabalin · DIN 02394243 · $0.2324
Auro-Pregabalin · DIN 02433877 · $0.2324
Bio-Pregabalin · DIN 02541130 · $0.2324
Co Pregabalin · DIN 02402920 · $0.2324
Lyrica · DIN 02268426 · $0.2324
M-Pregabalin · DIN 02467305 · $0.2324
Mar-Pregabalin · DIN 02417537 · $0.2324
Mint-Pregabalin · DIN 02423812 · $0.2324
NRA-Pregabalin · DIN 02479125 · $0.2324
Nat-Pregabalin · DIN 02494868 · $0.2324
PMS-Pregabalin · DIN 02359618 · $0.2324
Pregabalin · DIN 02403706 · $0.2324
Pregabalin · DIN 02405547 · $0.2324
Ran-Pregabalin · DIN 02392828 · $0.2324
Sandoz Pregabalin · DIN 02390825 · $0.2324
Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02435985
Shortage record checked October 6, 2026
Lyrica · DIN 02268426 · 50 mg · capsule
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Savings card: RxHelp ONE lists Lyrica (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Lyrica · DIN 02268426
Manufacturer: Upjohn Canada ULC; listing date 2013-04-30
Health Canada: Marketed since 2023-05-11 · brand LYRICA · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Bgp pharma ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.2324 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02268426)
Source record
DIN 02268426: Lyrica
Raw flags: sec3=Y
Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id UJC
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $1.6034; ministry $0.2324
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02268426
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75380
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324
Ach-Pregabalin · DIN 02449846 · $0.2324
Apo-Pregabalin · DIN 02394243 · $0.2324
Auro-Pregabalin · DIN 02433877 · $0.2324
Bio-Pregabalin · DIN 02541130 · $0.2324
Co Pregabalin · DIN 02402920 · $0.2324
Jamp-Pregabalin · DIN 02435985 · $0.2324
M-Pregabalin · DIN 02467305 · $0.2324
Mar-Pregabalin · DIN 02417537 · $0.2324
Mint-Pregabalin · DIN 02423812 · $0.2324
NRA-Pregabalin · DIN 02479125 · $0.2324
Nat-Pregabalin · DIN 02494868 · $0.2324
PMS-Pregabalin · DIN 02359618 · $0.2324
Pregabalin · DIN 02403706 · $0.2324
Pregabalin · DIN 02405547 · $0.2324
Ran-Pregabalin · DIN 02392828 · $0.2324
Sandoz Pregabalin · DIN 02390825 · $0.2324
Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: resolved shortage (ended May 12, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02268426
Shortage record checked October 6, 2026
Other products in the same Health Canada class (N02BF): coverage varies; not interchangeable
- Gabapentin (Neurontin): general benefit, not a benefit
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered
Matched class: 28:12 Anticonvulsants
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, VALPROATE SODIUM
Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, LAMOTRIGINE, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PRIMIDONE, TOPIRAMATE, VALPROIC ACID
28:12 Anticonvulsants
· 69 products · General benefit (49), Off-Formulary Interchangeable, not an ODB benefit (20) · strengths: 100mg, 300mg, 400mg, 600mg, 800mg · Cap, Tab
· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2),
Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab
· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab
· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab
· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L
· 28 products · General benefit (25), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3) · strengths: 25mg, 100mg, 150mg · Tab
· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab
· 4 products · General benefit (3),
Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)
· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab
· 54 products ·
Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab
· 5 products · General benefit · strengths: 50mg/mL · O/L
· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 250mg, 500mg · Cap, Ent Cap
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:12
and 11 more
Full class listing
Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs
Same formulary class, not same indication: class membership alone does not establish equivalent uses.